Etiology and Outcome of XXXX From a Single Center in China: A 10-Year Review.

@entity1 @entity8 @entity740 @entity1988 @entity1200 @entity810 @entity631
BACKGROUND: The disease spectrum of crescentic @entity631 ( @entity631 ) has been described in only a few previous studies, and detailed epidemiologic data from China are unavailable to date. STUDY DESIGN: Case series. SETTING _ @entity1 : 528 @entity1 with biopsy-proven crescentic @entity631 in 2003 to 2013 from a single center. PREDICTOR: Crescentic @entity631 was classified into 3 types according to immunofluorescence findings: type I was defined as linear deposition of immunoglobulins along the glomerular basement membrane; type II, as glomerular deposition of immune complex; and type III, as @entity1200 . OUTCOMES: Demographic, clinical, and serologic characteristics. RESULTS: Of 528 cases identified, 208 (39.4%) were @entity1 , with a mean age of 37.6  16.4 (SD) years at kidney biopsy. 61 (11.6%) @entity1 had type I crescentic @entity631 , 331 (62.7%) had type II ( @entity1988 , 34.3%; immunoglobulin A [IgA] @entity8 , 17.4%), and 136 (25.8%) had type III. Proportions of @entity1 with @entity810 ( @entity810 ), acute @entity8 without @entity810 , and @entity740 were 86.9%, 0%, and 13.1% for type I; 42.0%, 19.6%, and 38.4% for type II; and 84.6%, 2.9%, and 12.5% for type III crescentic @entity631 , respectively. Serum antineutrophil cytoplasmic antibodies were detected in 11 (18.0%) @entity1 with type I, 15 (4.5%) with type II, and 117 (86.0%) with type III. Anti-glomerular basement membrane antibodies were found in 60 (98.4%) @entity1 with type I, 3 (0.9%) with type II, and 5 (3.7%) with type III. 5-year cumulative renal survival rates for @entity1 with types I, II, and III were 17.6%, 70.1%, and 44.3%, respectively. LIMITATIONS: Retrospective study, single-center experience. CONCLUSIONS: @entity1988 may be the most common type of crescentic @entity631 in China, followed by pauci-immune crescentic @entity631 and @entity8 . Almost half the @entity1 presented with @entity810 , whereas 28.8% of cases showed @entity740 . Clinical manifestations and outcomes varied according to crescentic @entity631 type. The distinction between subtypes based on immunofluorescence and serologic findings has important implications for therapy and outcome.
